First Majestic Silver Shares Rise 8.12%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy AG?
Mixed options sentiment in First Majestic Silver (AG), with shares up $1.78, or 8.12%, near $23.77. Options volume relatively light with 71k contracts traded and calls leading puts for a put/call ratio of 0.44, compared to a typical level near 0.38. Implied volatility (IV30) dropped 1.51 near 92.78, in the highest 10% of observations over the past year, suggesting an expected daily move of $1.39. Put-call skew steepened, indicating increased demand for downside protection.Looking ahead: First Majestic Silver (AG) will report earnings before the open on 2026-02-19.Option markets are pricing in a 50% probability of a move greater than 9.01% or $2.14.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AG
Wall Street analysts forecast AG stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 22.600
Low
19.03
Averages
22.18
High
24.50
Current: 22.600
Low
19.03
Averages
22.18
High
24.50
About AG
First Majestic Silver Corp. is a mining company. The Company is focused on silver and gold production in Mexico and the United States. It owns and operates approximately 350,000 hectares of land package, which include the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, the La Encantada Silver Mine, and a 70% joint venture interest in the Cerro Los Gatos Silver Mine as well as a portfolio of development and exploration assets, including the Jerritt Canyon Gold project located in northeastern Nevada, United States. The San Dimas Silver/Gold Mine is located over 130 kilometers (km) northwest of the city of Durango, Durango State, Mexico. The Santa Elena Silver/Gold Mine is located over 150 km northeast of the city of Hermosillo, Sonora, Mexico. The La Encantada Silver Mine is an underground mine located in the northern Mexico State of Coahuila, 708 km northeast of Torreon. The Cerro Los Gatos Mine is located around 120 kms south of Chihuahua City, Mexico.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
First Majestic Silver Reports Record Quarterly Revenue
- Significant Revenue Growth: First Majestic Silver's Q4 revenue surged 169% year-over-year to $463.9 million, significantly exceeding Wall Street's estimate of $403.8 million, indicating strong performance and increased market demand in the silver sector.
- Profit Turnaround: The company reported a net profit of $105.2 million, a substantial recovery from a $13.5 million loss a year earlier, showcasing successful operational efficiency and strategic shifts, although earnings per share of $0.17 fell short of analysts' expectations of $0.20.
- Silver Sales Contribution: Notably, 60% of total Q4 revenue stemmed from silver sales, highlighting the company's dominant position in the silver market and ongoing sales growth potential, which further strengthens its competitive edge.
- Cash Dividend Announcement: The company declared a quarterly cash dividend of $0.0083 per share, reflecting its commitment to shareholder returns and indicating improved financial health following the profit recovery.
See More
First Majestic Silver Reports Record Q4 Earnings and Production
- Record Silver Production: First Majestic Silver achieved a record production of 4.2 million ounces of silver in Q4 2025, representing a 77% increase from 2.4 million ounces in Q4 2024, which not only enhances the company's market position but also lays a solid foundation for future growth.
- Significant Revenue Growth: The company reported revenue of $463.9 million for Q4, a remarkable 169.2% increase year-over-year, reflecting strong performance in the silver market and effective operational strategies.
- Record Free Cash Flow: Free cash flow reached a record $250.4 million in Q4, a substantial increase from $68.4 million in Q4 2024, demonstrating significant improvements in cash management and profitability.
- EBITDA Surge: The company's EBITDA for the quarter was $338.8 million, a dramatic increase of 276.8% compared to $62.0 million in Q4 2024, indicating exceptional performance in cost control and profitability.
See More
First Majestic Silver Set to Announce Q4 Earnings with Strong EPS Estimates
- Earnings Announcement: First Majestic Silver is set to release its Q4 earnings on February 19 before market open, with a consensus EPS estimate of $0.23, reflecting a substantial year-over-year increase of 666.7%, indicating a significant improvement in profitability.
- Historical Performance Review: Over the past two years, First Majestic has only beaten EPS estimates 13% of the time, while it has exceeded revenue estimates 50% of the time, suggesting a relatively unstable performance in meeting earnings forecasts.
- Recent Estimate Changes: In the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting increased analyst confidence in the company's future earnings potential, which could positively impact the stock price.
- Market Reaction Analysis: The recent rating upgrades for First Majestic and the $300 million offering of convertible senior notes indicate market recognition of its growth potential, likely attracting more investor interest.
See More
Novartis' Oral Remibrutinib Shows Positive Phase 3 Trial Results
- Trial Success: Novartis' pivotal Phase 3 RemIND trial for oral remibrutinib in chronic inducible urticaria (CIndU) met its primary endpoint, achieving significantly higher complete response rates compared to placebo, indicating the drug's potential in treatment.
- First Targeted Therapy: The data signifies remibrutinib's potential as the first targeted therapy for CIndU, with Global Head of Immunology Development Angelika Jahreis highlighting its positive trial results as a foundation for recent FDA approval in chronic spontaneous urticaria.
- Regulatory Progress: Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for remibrutinib's approval in symptomatic dermographism, enhancing its market position in urticaria treatment.
- Strong Stock Performance: Novartis shares rose 0.98% to $167.80 in premarket trading on Wednesday, reaching a new 52-week high, reflecting strong buying pressure, although the RSI of 83.54 suggests potential for a pullback.
See More
First Majestic Silver Stock Plummets 9% Amid Falling Precious Metal Prices
- Significant Stock Drop: First Majestic Silver's stock plummeted 9% by 10:55 a.m. Tuesday, primarily due to the ongoing decline in gold and silver prices, reflecting investor concerns about the company's future profitability.
- Volatile Precious Metal Prices: Gold prices have fallen from a record high of $5,419.80 per ounce on January 28 to the current $4,878, while silver has dropped from $116.58 to $73.40, casting a shadow over First Majestic's earnings outlook.
- Poor Earnings Expectations: Analysts predict that First Majestic will report earnings of $0.23 per share in the upcoming Q4 report, which is seven times the profit for Q4 2024, but with a full-year estimate of only $0.34, indicating weak growth prospects.
- Valuation Concerns: With First Majestic's stock priced around $21 and a P/E ratio exceeding 61, investors selling off shares ahead of earnings may be justified in their concerns regarding the company's high valuation and future profitability.
See More
HIVE Digital Technologies Reports Larger Than Expected Quarterly Losses
- Quarterly Losses: HIVE Digital Technologies reported a quarterly loss of $0.38 per share, significantly exceeding the analyst consensus estimate of a $0.07 loss, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales totaled $93.111 million, falling short of the analyst consensus estimate of $96.975 million, reflecting weak market demand that may lead to declining future performance.
- Stock Price Reaction: In pre-market trading, HIVE's shares fell by 2.3% to $2.16, indicating a negative investor reaction to the earnings report, which could impact the company's short-term financing capabilities.
- Overall Market Trend: U.S. stock futures were broadly lower, with Nasdaq 100 futures dropping over 150 points, reflecting a bearish market sentiment that may have a ripple effect on HIVE and other tech stocks.
See More
First Majestic Silver Reports Record Quarterly Revenue
- Significant Revenue Growth: First Majestic Silver's Q4 revenue surged 169% year-over-year to $463.9 million, significantly exceeding Wall Street's estimate of $403.8 million, indicating strong performance and increased market demand in the silver sector.
- Profit Turnaround: The company reported a net profit of $105.2 million, a substantial recovery from a $13.5 million loss a year earlier, showcasing successful operational efficiency and strategic shifts, although earnings per share of $0.17 fell short of analysts' expectations of $0.20.
- Silver Sales Contribution: Notably, 60% of total Q4 revenue stemmed from silver sales, highlighting the company's dominant position in the silver market and ongoing sales growth potential, which further strengthens its competitive edge.
- Cash Dividend Announcement: The company declared a quarterly cash dividend of $0.0083 per share, reflecting its commitment to shareholder returns and indicating improved financial health following the profit recovery.
See More
First Majestic Silver Reports Record Q4 Earnings and Production
- Record Silver Production: First Majestic Silver achieved a record production of 4.2 million ounces of silver in Q4 2025, representing a 77% increase from 2.4 million ounces in Q4 2024, which not only enhances the company's market position but also lays a solid foundation for future growth.
- Significant Revenue Growth: The company reported revenue of $463.9 million for Q4, a remarkable 169.2% increase year-over-year, reflecting strong performance in the silver market and effective operational strategies.
- Record Free Cash Flow: Free cash flow reached a record $250.4 million in Q4, a substantial increase from $68.4 million in Q4 2024, demonstrating significant improvements in cash management and profitability.
- EBITDA Surge: The company's EBITDA for the quarter was $338.8 million, a dramatic increase of 276.8% compared to $62.0 million in Q4 2024, indicating exceptional performance in cost control and profitability.
See More
First Majestic Silver Set to Announce Q4 Earnings with Strong EPS Estimates
- Earnings Announcement: First Majestic Silver is set to release its Q4 earnings on February 19 before market open, with a consensus EPS estimate of $0.23, reflecting a substantial year-over-year increase of 666.7%, indicating a significant improvement in profitability.
- Historical Performance Review: Over the past two years, First Majestic has only beaten EPS estimates 13% of the time, while it has exceeded revenue estimates 50% of the time, suggesting a relatively unstable performance in meeting earnings forecasts.
- Recent Estimate Changes: In the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting increased analyst confidence in the company's future earnings potential, which could positively impact the stock price.
- Market Reaction Analysis: The recent rating upgrades for First Majestic and the $300 million offering of convertible senior notes indicate market recognition of its growth potential, likely attracting more investor interest.
See More
Novartis' Oral Remibrutinib Shows Positive Phase 3 Trial Results
- Trial Success: Novartis' pivotal Phase 3 RemIND trial for oral remibrutinib in chronic inducible urticaria (CIndU) met its primary endpoint, achieving significantly higher complete response rates compared to placebo, indicating the drug's potential in treatment.
- First Targeted Therapy: The data signifies remibrutinib's potential as the first targeted therapy for CIndU, with Global Head of Immunology Development Angelika Jahreis highlighting its positive trial results as a foundation for recent FDA approval in chronic spontaneous urticaria.
- Regulatory Progress: Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for remibrutinib's approval in symptomatic dermographism, enhancing its market position in urticaria treatment.
- Strong Stock Performance: Novartis shares rose 0.98% to $167.80 in premarket trading on Wednesday, reaching a new 52-week high, reflecting strong buying pressure, although the RSI of 83.54 suggests potential for a pullback.
See More
First Majestic Silver Stock Plummets 9% Amid Falling Precious Metal Prices
- Significant Stock Drop: First Majestic Silver's stock plummeted 9% by 10:55 a.m. Tuesday, primarily due to the ongoing decline in gold and silver prices, reflecting investor concerns about the company's future profitability.
- Volatile Precious Metal Prices: Gold prices have fallen from a record high of $5,419.80 per ounce on January 28 to the current $4,878, while silver has dropped from $116.58 to $73.40, casting a shadow over First Majestic's earnings outlook.
- Poor Earnings Expectations: Analysts predict that First Majestic will report earnings of $0.23 per share in the upcoming Q4 report, which is seven times the profit for Q4 2024, but with a full-year estimate of only $0.34, indicating weak growth prospects.
- Valuation Concerns: With First Majestic's stock priced around $21 and a P/E ratio exceeding 61, investors selling off shares ahead of earnings may be justified in their concerns regarding the company's high valuation and future profitability.
See More
HIVE Digital Technologies Reports Larger Than Expected Quarterly Losses
- Quarterly Losses: HIVE Digital Technologies reported a quarterly loss of $0.38 per share, significantly exceeding the analyst consensus estimate of a $0.07 loss, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales totaled $93.111 million, falling short of the analyst consensus estimate of $96.975 million, reflecting weak market demand that may lead to declining future performance.
- Stock Price Reaction: In pre-market trading, HIVE's shares fell by 2.3% to $2.16, indicating a negative investor reaction to the earnings report, which could impact the company's short-term financing capabilities.
- Overall Market Trend: U.S. stock futures were broadly lower, with Nasdaq 100 futures dropping over 150 points, reflecting a bearish market sentiment that may have a ripple effect on HIVE and other tech stocks.
See More
